The Food and Drug Administration approved ORZEYFUL (oveporexton) on August 5, 2026, clearing the first medicine designed to treat narcolepsy type 1 as one disorder rather than a list of separate symptoms [1]. It is an oral tablet taken twice daily [1].
Narcolepsy type 1 comes from the loss of orexin, the brain signal that helps keep a person awake and steadies the boundary between sleeping and waking. Losing it brings on the disorder's core problems: overwhelming daytime sleepiness and cataplexy, the sudden loss of muscle tone. ORZEYFUL is an orexin receptor 2 agonist, which means it restores that missing signaling directly instead of managing each symptom on its own [1].
Two Phase 3 trials carried the approval. In FirstLight and RadiantLight, the drug delivered what Takeda describes as "statistically significant improvements across the full range of symptoms of the disease," including excessive daytime sleepiness, cataplexy, and health-related quality of life [1]. The release did not give the exact size of those improvements.
About 120,000 people in the United States have narcolepsy type 1 [1]. For them the approval closes a long gap, because until now the available options treated the sleepiness or the cataplexy, not the deficiency behind both.
"The FDA approval of ORZEYFUL marks a new chapter for the narcolepsy type 1 community, as we introduce an entirely new class of medicine," Takeda president and chief executive officer Julie Kim said [1].
The drug is not on pharmacy shelves yet. A controlled substance scheduling review is expected to conclude within about 90 days, after which ORZEYFUL is set to become available through specialty pharmacies [1]. Until that review finishes, the approval is a milestone people can count on rather than a prescription they can fill.
